Wereport a uniquecase in which a57-year-old man with an8-yearhistoryoflaterecurrentpost-tympanostomy tube otorrhea (PTTO) 
Introduction
Most ofthe pathology that occurs in the middle ear and mastoid cavity is the result of eustachian tube dysfunction. A failure of middle ear air pressure to equalize results in atelectasis that can lead to several potentially serious pathologies, including middle ear effusion, hearing loss, and cholesteatoma.
Although children are more likely to experience eustachian tube dysfunction because of their anatomy, adults can also experience complications of middle ear atelectasis. Indeed, chronic otitis media with effusion can affect some adults who have a long-term history of eustachian tube dysfunction. Affected adults may experience difficulty achieving middle ear aeration after an airplane flight or, more commonly, after an upper respiratory tract infection. Depending on the nature of the particular middle ear pathology, short-or long -term ventilation may be required.
One of the most troublesome complications of tympanostomytube placement is post-tympanostomytube otorrhea (PTTO).I The results of microbiologic studies indicate that the typical bacterial culprits in PTTO are
Streptococcus pneumoniae, Haemophilus injluenzae, Pseudomonas aeruginosa, and Staphylococcus aureus?
In this article, we describe what we believe is the first reported case of late recurrent PTTO secondary to an aerobic endospore-forming bacillus in an adult.
Case report
Thepatientwas a 57-year-oldrnanwho had been followed in our ear clinic for the previous 5 years for the treatment ofleft-sided otorrhea that would recur approximately every 4 or 5 months. He had a history of recurrent otitis media with effusion that had begun when he was a child and had continued into adulthood. Approximately 8 years earlier, he had undergone placement of bilateral ventilation tubes to treat the chronic otitis media with effusion, and he experienced a subsequent resolution of symptoms and restoration of his hearing. He had been compliant with standard dry-ear precautions.
As a result of the ventilation tube in his right ear, which had extruded approximately 2 years after it was placed, the patient had a chronic central perforation in his right tympanic membrane. However, the perforation had caused only minimal hearing loss and no otorrhea.
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The ventilation tube in the left ear was still in place. During evaluation of another recurrence of the patient's left-sided otorrhea, examination revealed fluid but no granulation tissue surrounding the grommet. The otorrhea was not purulent; rather, its consistency was similar to that of serous fluid in that it was more viscous and darker. Crusting was noted on the outer ear secondary to the desiccated otorrhea (figure 1).
The ventilation tube was removed from the left ear without complication, and both the tube and a sample ofthe otorrhea were sent for culture. Microbacteriologic analysis of both identified aerobic endospore-forming bacilli (figure 2). The patient was managed with water precautions and a 7-day course ofpolymyxin Beardrops, and his otorrhea resolved. No recurrence of otorrhea was noted during 5 months ofadditional follow-up, despite the fact that the left tympanic membrane contained a persistent central perforation ( figure 3 ). 
Discussion
Types ofPTTO. Kayet aP used data from a meta-analysis to classify post-tympanostomy tube otorrhea (PTTO) as early, late, chronic, and recurrent:
• Early PTTO occurs within 4 weeks of tube placement. Its reported incidence is 16%. 3 The use of topical antibiotics immediately following tube placement has been shown to prevent early PTTO in many cases. ' • Late FTTO occurs more than 4 weeks after tube placement. Its reported incidence is 26%.3 Late PTTO is usually caused by (1) pathologies similar to those responsible for acute otitis media or (2) external contamination.
• Chronic PTTO refers to otorrhea that lasts longer than 3 months. Its reported incidence is 4%.3 Bacterial biofilms have been implicated as the etiology.
• Recurrent PTTO refers to 3 or more discrete episodes separated by periods of clearing. Its reported incidence is 7%.3,5
Risk factors. Gates et al proposed a comprehensive list ofextrinsic and intrinsic risk factors for the different types ofPTTO. 6 These factors include water contamination, foreign-body reactions, the presence of chronic bacterial biofilms in the middle ear, biofilm adherence to a ventilation tube, the time of year, and current upper respiratory tract infections.
According to Hochman et al, water contamination of the middle ear can provide a medium for bacterial growth, especiallyPaeruginosa. 4 In our case, water infil-68" www.entjournal.com tration was less likely because the patient was observing dry-ear precautions. A foreign-body reaction cannot be completely ruled out as the cause of the otorrhea in our patient, but it is noteworthy that no granulation tissue was seen surrounding the tube prior to its removal.
Barakate et al examined the role ofbiofilm formation in chronic PTTO.7 They described a case of persistent PTTO in a child who did not respond to treatment despite the administration of culture-directed ototopical and systemic antibiotics (microbiologic analysis had confirmed P aeruginosa). Therefore, a biofilm was suspected as the culprit, and scanning electron microscopy confirmed the presence of a biofilm attached to the tube.
In 2001, Post published his investigation of the forma- In clinical trials of 2 to 52weeks duration, epistaxis and nasal ulcerations were observed more frequently and some epistaxis events were more severe in patients treated with ONASL Nasal Aerosol than those who received placebo. In the 52-week safety trial in patients with perennial allergic rhinitis, nasal erosions were identified in 4 of 415 patients and a nasal ulceration was identified in 1 of 415 patients treated with ONASL Nasal Aerosol. No nasal erosions or ulcerations were reported for patients who received placebo. Patients using ONASL Nasal Aerosol over several months orlonger should be examined periodically for possible changes in the nasal mucosa. If an adverse reaction (e.g., erosion, ulceration) is noted, discontinue ONASL Nasal Aerosol. (see Adverse Reactions (6.1)].
Candida Infection: In previous clinical trials with an aqueous formulation 01 beclomethasone dipropionate administered intranasally, localized infections of the nose and pharynx with Candida aibicans had been reported. There were noinstances of similar inlections observed in clinical trials with ONASL Nasal Aerosol. II such an infection develops, it may require treatment with appropriate local therapy and discontinuation of ONASL Nasal Aerosol treatment. Thus, patients using ONASL Nasal Aerosol over several months orlonger should be examined periodically for evidence 01 Candida infection.
Nasal Septal Perforation: Instances of nasal septal perforation have been reported in patients lollowing the intranasal application of beclomethasone dipropionate. There were no instances of nasal septal perforation observed in clinical trials with ONASL Nasal Aerosol. Impaired Wound Healing: Because of the inhibitory effect of corticosteroids on wound healing, patients who have experienced recent nasal septal ulcers, nasal surgery, or nasal trauma should not use ONASL Nasal Aerosol until healing has occurred.
Glaucoma and Cataracts
Use of intranasal and inhaled corticosteroids may result in the development 01 glaucoma and/or cataracts. Therefore, close monitoring is warranted in patients with achange invision orwith ahistory 01 increased intraocular pressure, glaucoma, and/or cataracts.
Glaucoma and cataract formation was evaluated with ocular assessments that included intraocular pressure measurements and slitlamp examinations in245 adolescent and adult patients (12years 01 age and older) with perennial allergic rhinitis who were treated with ONASL Nasal Aerosol 320 mcg dally (N=197) or placebo (N=48) for upto 52weeks. In94% of patients, intraocular pressure (lOP) remained within the normal range «21 mmHg) during the treatment portion 01 the trial. There were 10patients (5%) treated with ONASL Nasal Aerosol and 1 patient (2%) treated with placebo that had intraocular pressure thatincreased above normal levels (2:21 mmHg) and greater than baseline during the treatment portion of the trial. Two of these occurrences in patients treated with ONASL Nasal Aerosol were reported as adverse reactions, one serious. No instances ofcataract formation or other clinically significant ocular incidents were reported in this52-week safety trial {see Adverse Reactions (6.1)].
5.3Hypersensitivity Reactions Including Anaphylaxis Hypersensitivity reactions including anaphylaxis, angioedema, urticaria, and rash have been reported following administration of beclomethasone dipropionate nasally administered and lnhalationally administered products. Angioedema, urticaria, and rash have been reported following administration of ONASL Nasal Aerosol. Discontinue ONASL Nasal Aerosol if any such reactions occur {see Contraindications (4)].
5.4Immunosuppression
Persons who are using drugs that suppress the immune system (e.g., corticosteroids) are more susceptible to infections than healthy individuals. Chickenpox and measles, for example, can have a more serious or even fatal course in susceptible children or adults using corticosteroids. In children or adults who have not had these diseases or been properly immunized, particular care should be taken to avoid exposure. How the dose, route, and duration of corticosteroid administration affect the risk of developing a disseminated infection is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also notknown. If a patient is exposed to chickenpox, prophyiaxis with varicella zoster immune globulin (VZIG) may be indicated. If a patient is exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated (see the respective package inserts forcomplete VZIG and IG prescribing information). II chickenpox or measles develops, treatment with antiviral agents may be considered. . Short-Term 12:-6 Weeks) Trials: Overall, the incidence of adverse reactions did notdiffer appreciably between patients treated with ONASL Nasal Aerosol and t~ose~ho were treated With placebo. Less than 2% of patients in the clinical trials discontlnued treatment because of adverse reactions with the rate of withdrawal among patients who recelved.ONASL Nasal Aerosol similar to or lower than the rate among patients who received placebo. Table 1 displays the common adverse reactions (2:1% and greater than placebo-treated patients) Na~al ulcerations occurred in 2 patients treated with placebo and in 1 patient treated With ONASL Nasal Aerosol. There were no differences in the incidence of adverse reactions based on gender or race. Clinical trials did not have sufficient numbers of patients aged 65years and older to determine whether they respond differently than younger patients.
Long-Term 52-Week SafelY Trial: Ina 52-week placebo-controlled long-term safety trial in patients with PAR, 415 patients (128 males and 287 females aged 12 to 74 years) were treated with ONASL Nasal Aerosol at a dose of 320 mcg once daily and 111 patients (44 males and 67females, aged 12to 67years) were treated with placebo. Of the 415 patients treated with ONASL Nasal Aerosol, 219 patients were treated for 52 weeks and 196 patients were treated for 30 weeks. While most adverse events were simiiar in type and rate between the treatment groups, epistaxis occurred more frequently in patients who received ONASL Nasal Aerosol (45 outof 415,11%) than in patients who received placebo (2 outof 111, 2%). Epistaxis also tended to be more severe in patients treated with ONASL Nasai Aerosol. In 45 reports of epistaxis in patients who received ONASL Nasal Aerosol, 27,13, and 5 cases were ofmild, moderate, and severe intensity, respectively, while Controlled clinical trials have shown that intranasal corticosteroids may cause a reduction in growth velocity in pediatric patients. This effect has been observed inthe absence of laboratory evidence of hypothalamic-pituitary-adrenal (HPA) axis suppression, suggesting that growth velocity is a more sensitive indicator of systemic corticosteroid exposure inpediatric patients than some commonly used tests of HPA-axis function. The long-term effects of reduction in growth velocity associated with intranasal corticosteroids, including the impact onfinal adult height, are unknown. The potential for "catch-up" growth following discontinuation of treatment with intranasal corticosteroids has not been adequately studied. The growth of pediatric patients receiving intranasal corticosteroids, including QNASL Nasal Aerosol, should be monitored routinely (e.g., via stadiometry).
A 12-month, randomized, controlled clinical trial evaluated the effects of QVAR®, an orally inhaied HFA beclomethasone dipropionate product, without spacer versus chlorofluorocarbon-propelled (CFC) beclomethasone dipropionate with large volume spacer on growth in children with asthma ages 5 to 11 years. Atotal of 520 patients were enrolled, of whom 394 received HFA-beclomethasone dipropionate (100 to400 meg/day ex-valve) and 126 received CFC-beclomethasone dipropionate (200 to 800 mcg/day ex-valve). When comparing results at month 12 to baseline, the mean growth velocity inchildren treated with HFA-beclomethasone dlproplonate was approximately 0.5 cm/year less than that noted with children treated with CFC-beclomethasone dipropionate via large volume spacer. The potential growth effects of prolonged treatment should be weighed against the clinical benefits obtained and the risks/benefits oftreatment alternatives.
The potential for QNASL Nasal Aerosol to cause reduction in growth velocity insusceptible patients orwhen given athigher than recommended dosages cannot be ruled out.
8.5Geriatric Use Clinical trials of QNASL Nasal Aerosol didnotinclude sufficient numbers of SUbjects aged 65years and older to determine whether they responded differently than younger subjects. Other reported clinical experience has notidentified differences in responses between the elderly and younger patients. In general, administration to elderly patients should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
10OVERDOSAGE
Chronic overdosage may result in signs/symptoms of hypercorticism [see Warnings and Precautions (5.5)). There are nodata available on the effects ofacute orchronic overdosage with QNASL Nasal Aerosol. the reports ofepistaxis inpatients who received placebo were of mild (1)and moderate (1) intensity. Seventeen patients treated with QNASL Nasal Aerosol experienced adverse reactions that led towithdrawal from the trial compared to 3 patients treated with placebo. There were 4 nasal erosions and 1 nasal septum ulceration which occurred in patients who received QNASL Nasal Aerosol, and no erosions or ulcerations noted in patients who received placebo. No patient experienced anasal septum perforation during the trial.
6.2Postmarketing Experience In addition to adverse reactions reported from clinical trials for QNASL Nasal Aerosol, the following adverse events have been reported during use of other intranasal and inhaled formulations of beclomethasone dipropionate. Because these reactions are reported voluntarily from a population of uncertain size, it is notalways possible toreliably estimate their frequency orestablish acausal relationship todrug exposure. These events have been chosen for inclusion due to either their seriousness, frequency of reporting, or causal connection to beclomethasone dipropionate oracombination ofthese factors.
Intranasal beclomethasone dipropionate: Nasal septal perforation, glaucoma, cataracts, loss oftaste and smell, and hypersensitivity reactions including anaphylaxis, angioedema, rash, and urticaria have been reported following intranasal administration of beclomethasone dipropionate.
Inhaled beclomethasone dipropionate: Hypersensitivity reactions, inciuding anaphylaxis, angioedema, rash, urticaria, and bronchospasm have been reported following the oral inhalation of beclomethasone dipropionate.
DRUG INTERACTIONS
No drug interaction studies have been performed with QNASL Nasal Aerosol. 8 USE INSPECIFIC POPULATIONS 8.1 Pregnancy Teratogenic Effects: Pregnancy Category C There are noadequate and well-controlled clinical trials in pregnant women treated with QNASL Nasal Aerosol. Beclomethasone dipropionate was teratogenic and embryocidal inthe mouse and rabbit although these effects were notobserved In rat.~NASL Nasal Aerosol should be used during pregnancy only if the potential benefit Justifies the potential risk to the fetus. Experience with oral corticosteroids since their introduction in pharmacologic, as opposed to physiologic, doses suggests that rodents are more prone to teratogenic effects from corticosteroids than humans.
Beclomethasone dipropionate administered SUbcutaneously was teratogenic and embryocidal in the mouse and rabbit at doses approximately twice the maximu~recommended human daily intranasal dose (MRHDID) inadults (on amg/m 2 asl s at maternal doses of 0.1 and 0.025 mg/kg/day in mice and rabbits, respectively). No teratogenicity orembryocidal effects were seen in rats atapproximately 460 times MRHDID (in adults on a mg/m 2 basis at a maternal inhalation dose of . 15mg/kg/day).
N~n. tion ofbiofilms on the middle ear mucosa ofa chinchilla injected with nontypeable H influenzae? Until then, it had long been believed that otitis media with effusion is sterile and therefore not infectious in nature because bacteria could not be cultured from most middle ear effusions. However, Post's work definitely identified organisms in a biofilm form. It has been theorized that the limitations of culture in detecting bacteria in PTTO are attributable either to slowly growingbacteria, fastidious bacteria, dormant bacteria, or bacteria protected by biofilms." In our case, we initially hypothesized that the major cause of our patient's otorrhea was a biofilm that had encased the ventilation tube, even though we did not use scanning electron microscopy to confirm the presence of any such biofilm. However, microbiologic analysis and Gram staining did not identify any of the known microbes that are linked to biofilms. Even so, a biofilm cannot be completely ruled out as a possible cause in our patient because our culture technique might have limited our ability to identify one.
Endospore-formingbacilli. Toour surprise, microbiologic analyses of the tube removed from our patient's left ear and ofhis otorrhea demonstrated the presence ofonly minimal colonies ofaerobic endospore-forming bacilli. No otherorganisms were detected. However,considering the pathophysiology and life cycle of this unique type of organism, it should not come as a complete surprise that this resistant bacterium could be responsible for our patient's late recurrent PTTO. The unusual resistance of the resting endospores to chemical and physical agents, the developmental cycle of endospore formation, their morphology, and the production of their own antibiotics provides these bacteria with a survival advantage.'? In our patient, the unique life cycle might have allowed B subtilis to survive in a middle ear that was open to the external environment. Furthermore, our patient's repeated treatment with ototopical antibiotics provided a favorable environment for this organism to flourish, as selective antibiotic pressure can provide a safe medium by inhibiting gram-negative bacteria.
Although it is difficult to confirm the exact cause of the late recurrent PTTO in our patient, it is likely that B subtilis, which is known to be resistant to treatment, was the culprit. While several other factors described in this report might have contributed to our patient's otorrhea, we believe that the endospore-forming bacteria played the primary role.
In conclusion, our case shows that aerobic endosporeforming bacteria can be added to the possible list of causes in the differential diagnosis of PTTO. Regardless of the suspected etiology, however, a patient with persistent or recurrent PTTO should consider having the ventilation tube removed.
